MONDELEZ INTERNATIONAL INC Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $61.47 (market cap $78.85B), while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 43.6× Recursion Pharmaceuticals Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.24% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MDLZ | RXRX | |
|---|---|---|
Market Cap | $78.85B | $1.81B |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $6.79 |
52-Week Low | $51.51 | $2.84 |
Enterprise Value | $99.19B | $1.33B |
Dividend Yield | 3.24% | — |
Signals from Pluang's Aura AI — not financial advice
MDLZ trades at $61.53, down 1.72% today, with a bullish technical outlook supported by moving averages and oversold RSI signals. The company reported strong Q2 2026 earnings, beating estimates with $0.73 EPS and raising organic sales guidance, driven by growth in emerging markets. Valuation ratios like P/E of 37.75 and P/S of 4.01 reflect premium pricing, while profitability remains solid with an 8.86% net income margin.
The stock offers upside to the $70.50 consensus price target, supported by analyst optimism and institutional buying, but faces risks from reliance on international sales and margin pressures. Earnings momentum and dividend stability provide a favorable outlook, though macroeconomic volatility could challenge growth.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Trailing returns across standard periods
Latest headlines on both assets
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →